BSEBoard Meeting4 Aug 2026 · 4 Aug 2026, 10:35 am

Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve This is to inform ....

AstraZeneca Pharma India Ltd · 506820

✦ AI SummaryResults

AstraZeneca Pharma India Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 to consider and approve the Un-audited Financial Results of the Company for the quarter ended June 30, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

AstraZeneca Pharma India Ltd - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Monday, August 10, 2026

Attachments (1)

📄

d2e689a7-586c-4214-b4e7-bfa7d2d22e62.pdf

pdf

Download →
View document text
August 4, 2026 The Manager - Listing National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400051 The Manager - Listing BSE Limited P J Towers, Dalal Street, Fort, Mumbai - 400001 Dear Sir/ Madam, Sub: Meeting of the Board of Directors of the Company to be held on Monday, August 10, 2026 Ref: Scrip Code – BSE: 506820, NSE: ASTRAZEN This is to inform that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Monday, August 10, 2026 inter alia to consider and approve the Un-audited Financial Results of the Company for the quarter ended June 30, 2026. We also confirm that the ‘Trading Window’ remains closed for all Designated Persons, from June 16, 2026 to August 12, 2026 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. We request you to please take the same on record. Thanking you, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer